Merck & Co., Inc. (MRK) shareholders
Close on Nov 16, 2026Market cap $356.41BP/E 115.6Yield 2.27%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 201,836,434 | 8.00% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 186,323,766 | 7.53% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MRK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 226,999,837 | 9.20% | $29.17B | +1,169,507 | 0.43% |
| Vanguard Capital Management LLC | 161,323,174 | 6.54% | $20.73B | +335,550 | 0.44% |
| State Street Corp | 120,413,256 | 4.88% | $15.57B | +1,087,583 | 0.46% |
| Wellington Management Group Llp | 86,249,283 | 3.50% | $11.08B | +1,934,312 | 1.91% |
| Vanguard Portfolio Management LLC | 67,738,969 | 2.75% | $8.70B | +434,664 | 0.39% |
| Geode Capital Management, LLC | 60,744,214 | 2.46% | $7.79B | +1,186,060 | 0.42% |
| Charles Schwab Investment Management Inc | 54,365,289 | 2.20% | $6.99B | +4,600,064 | 0.93% |
| Morgan Stanley | 48,641,158 | 1.97% | $6.25B | +1,008,671 | 0.33% |
| FMR LLC | 45,440,355 | 1.84% | $5.84B | +924,345 | 0.25% |
| JPMorgan Chase & Co | 43,886,420 | 1.78% | $5.68B | −9,086,563 | 0.31% |
| Fisher Asset Management, LLC | 38,516,263 | 1.56% | $4.95B | +12,079,979 | 1.47% |
| Norges Bank | 36,983,784 | 1.50% | $4.75B | New | 0.47% |
| Bank Of America Corp /De/ | 30,535,208 | 1.24% | $3.92B | −239,013 | 0.25% |
| Northern Trust Corp | 26,275,718 | 1.07% | $3.38B | −814,305 | 0.39% |
| Goldman Sachs Group Inc | 22,075,139 | 0.89% | $2.84B | +1,941,760 | 0.25% |
| Franklin Resources Inc | 19,548,585 | 0.79% | $2.51B | +3,281,380 | 0.54% |
| UBS Asset Management Americas Inc | 19,547,171 | 0.79% | $2.51B | −867,648 | 0.46% |
| Legal & General Group Plc | 18,873,343 | 0.76% | $2.43B | −665,202 | 0.51% |
| Invesco Ltd. | 18,611,171 | 0.75% | $2.39B | −3,243,930 | 0.19% |
| Price T Rowe Associates Inc /Md/ | 18,518,796 | 0.75% | $2.38B | −4,524,046 | 0.24% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 3,824 | 1.98B | 80.3% | 209 / 1632 | 1492 / 116 | 135M | 80M |
| Q1 2026 | 3,796 | 1.93B | 78.3% | 317 / 1461 | 1587 / 123 | 361M | 144M |
| Q4 2025 | 3,658 | 1.97B | 80.0% | 549 / 1377 | 1402 / 130 | 181M | 144M |
| Q3 2025 | 3,310 | 1.94B | 78.7% | 192 / 1364 | 1420 / 149 | 112M | 152M |
| Q2 2025 | 3,325 | 1.98B | 80.4% | 179 / 1299 | 1533 / 253 | 122M | 114M |
| Q1 2025 | 3,447 | 1.98B | 80.3% | 183 / 1347 | 1596 / 275 | 150M | 134M |
| Q4 2024 | 3,601 | 1.99B | 80.5% | 390 / 1321 | 1574 / 208 | 153M | 135M |
| Q3 2024 | 3,485 | 1.99B | 80.5% | 148 / 1525 | 1419 / 161 | 304M | 93M |
| Q2 2024 | 3,539 | 1.98B | 80.4% | 177 / 1607 | 1362 / 119 | 83M | 148M |
| Q1 2024 | 3,532 | 2.06B | 83.4% | 260 / 1412 | 1487 / 112 | 146M | 83M |
| Q4 2023 | 3,429 | 2.01B | 81.3% | 380 / 1245 | 1482 / 107 | 156M | 64M |
| Q3 2023 | 3,209 | 1.92B | 77.9% | 148 / 1296 | 1405 / 148 | 63M | 76M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
1,428 funds held MRK in Q2 2026, 53% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MRK | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 78,411,374 | 3.18% | $10.08B | 0.44% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 63,996,884 | 2.59% | $8.22B | 0.49% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 33,973,743 | 1.38% | $4.37B | 0.49% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 31,762,503 | 1.29% | $3.77B | 0.45% | May 31, 2026 |
| Schwab U.S. Dividend Equity ETF | 30,860,833 | 1.25% | $3.66B | 3.86% | May 31, 2026 |
| Vanguard Value Index Fund | 23,507,703 | 0.95% | $3.02B | 1.19% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 17,448,577 | 0.71% | $2.24B | 5.52% | Jun 30, 2026 |
| Vanguard Health Care Fund | 15,950,834 | 0.65% | $2.08B | 5.44% | Jul 31, 2026 |
| Vanguard Dividend Appreciation Index Fund | 13,974,148 | 0.57% | $1.82B | 1.39% | Jul 31, 2026 |
| Vanguard Institutional Index Fund | 13,407,864 | 0.54% | $1.72B | 0.49% | Jun 30, 2026 |
| Vanguard Equity Income Fund | 12,367,541 | 0.50% | $1.59B | 2.43% | Jun 30, 2026 |
| Vanguard High Dividend Yield Index Fund | 9,961,116 | 0.40% | $1.30B | 1.31% | Jul 31, 2026 |
| Vanguard Wellington Fund | 9,932,268 | 0.40% | $1.18B | 0.95% | May 31, 2026 |
| Washington Mutual Investors Fund | 8,487,046 | 0.34% | $1.11B | 0.51% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 7,454,549 | 0.30% | $885.00M | 4.66% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert M. Davis | Chairman, CEO & President, Director | 450,351 | 0.02% | May 7, 2026 |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 114,291 | 0.00% | Nov 16, 2026 |
| David R. Maraldo | EVP & Pres. MMD | 23,769 | 0.00% | Oct 22, 2026 |
| Gaurav K. Gupta | EVP, CIDO | 750 | 0.00% | Sep 1, 2026 |
| Chirfi Guindo | EVP, Access, Policy & Comms | 36,670 | 0.00% | Aug 13, 2026 |
| Jennifer Zachary | EVP, General Counsel | 125,824 | 0.01% | Aug 13, 2026 |
| David Michael Williams | EVP,Chief Info&Digital Officer | 31,716 | 0.00% | Aug 7, 2026 |
| Dalton E. Smart III | SVP Fin. - Global Controller | 9,388 | 0.00% | May 7, 2026 |
| Betty D. Larson | EVP, Chief HR Officer | 13,774 | 0.00% | May 7, 2026 |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 21,895 | 0.00% | May 7, 2026 |
| Brian Foard | EVP, Specialty, Pharma, & ID | – | – | May 7, 2026 |
| Caroline Litchfield | EVP & CFO | 92,301 | 0.00% | May 7, 2026 |
| Dean Y. Li | Executive VP & President, MRL | 94,431 | 0.00% | May 7, 2026 |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 200,675 | 0.01% | May 1, 2026 |
| Joseph Romanelli | President, Human Health Int?l | 28,739 | 0.00% | Jan 28, 2026 |
| Cristal N. Downing | Chief Comm. & Public Afrs Ofcr | 0 | – | Nov 12, 2025 |
| Paul J. Diaz | Director | 296 | 0.00% | Nov 3, 2026 |
| Christine E. Seidman | Director | 100 | 0.00% | Oct 1, 2026 |
| Mary Ellen Coe | Director | 10 | 0.00% | Oct 1, 2026 |
| Surendralal Lanca Karsanbhai | Director | 1 | 0.00% | Oct 1, 2026 |
| Paul Rothman | Director | 100 | 0.00% | Jun 2, 2026 |
| Risa J. Lavizzo-Mourey | Director | 1,000 | 0.00% | Jun 2, 2026 |
| Stephen Mayo | Director | 100 | 0.00% | Jun 2, 2026 |
| Patricia F. Russo | Director | 13,148 | 0.00% | Jun 2, 2026 |
| Douglas M. Baker Jr | Director | 16,000 | 0.00% | Jun 2, 2026 |
| Kathy J. Warden | Director | 500 | 0.00% | Jun 2, 2026 |
| Inge G. Thulin | Director | 2,933 | 0.00% | Jun 2, 2026 |
| Pamela J. Craig | Director | 1,715 | 0.00% | Jun 2, 2026 |
| Thomas H. Glocer | Director | 5,100 | 0.00% | Jun 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Nov 12, 2026 | Sale | −58,185 | $148.01 | $8.61M | 112,955 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Nov 12, 2026 | Option exercise | +58,185 | $77.62 | $4.52M | 171,140 |
| Chirfi Guindo EVP, Access, Policy & Comms | Aug 13, 2026 | Sale | −10,000 | $135.00 | $1.35M | 36,613 |
| Jennifer Zachary EVP, General Counsel | Aug 12, 2026 | Option exercise | +13,433 | $84.71 | $1.14M | 125,824 |
| Jennifer Zachary EVP, General Counsel | Aug 12, 2026 | Sale | −80,315 | $133.46 | $10.72M | 45,509 |
| Jennifer Zachary EVP, General Counsel | Aug 12, 2026 | Option exercise | +41,494 | $117.89 | $4.89M | 112,391 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 12, 2026 | Sale | −600 | $132.04 | $79.22K | 110,167 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 12, 2026 | Sale | −11,099 | $131.61 | $1.46M | 110,767 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 11, 2026 | Sale | −5,427 | $132.35 | $718.26K | 121,866 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 11, 2026 | Sale | −7,410 | $131.33 | $973.16K | 127,293 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 10, 2026 | Sale | −20,784 | $130.43 | $2.71M | 134,703 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 6, 2026 | Sale | −4,945 | $130.23 | $643.99K | 155,787 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 6, 2026 | Sale | −300 | $131.02 | $39.31K | 155,487 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Aug 6, 2026 | Sale | −805 | $131.02 | $105.47K | 160,732 |
| Chirfi Guindo EVP, Access, Policy & Comms | Aug 6, 2026 | Sale | −15,000 | $131.00 | $1.97M | 46,613 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Option exercise | +2,686 | $84.71 | $227.53K | 20,898 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Option exercise | +6,311 | $73.73 | $465.31K | 24,523 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Sale | −6,311 | $128.72 | $812.35K | 18,212 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Sale | −2,686 | $128.72 | $345.74K | 18,212 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Sale | −9,709 | $128.72 | $1.25M | 18,212 |
| David R. Maraldo EVP & Pres. MMD | Aug 5, 2026 | Option exercise | +9,709 | $87.10 | $845.65K | 27,921 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Sale | −13,542 | $128.77 | $1.74M | 31,716 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Option exercise | +4,600 | $77.62 | $357.05K | 36,316 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Sale | −4,600 | $128.77 | $592.34K | 31,716 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Option exercise | +13,542 | $75.36 | $1.02M | 45,258 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Sale | −34,705 | $128.77 | $4.47M | 31,716 |
| David Michael Williams EVP,Chief Info&Digital Officer | Aug 5, 2026 | Option exercise | +34,705 | $73.73 | $2.56M | 66,421 |
| Dalton E. Smart III SVP Fin. - Global Controller | May 2, 2026 | Tax withholding | −132 | $112.16 | $14.81K | 9,388 |
| Dalton E. Smart III SVP Fin. - Global Controller | May 2, 2026 | Option exercise | +383 | $112.16 | $42.96K | 9,520 |
| David R. Maraldo EVP & Pres. MMD | May 2, 2026 | Option exercise | +552 | $112.16 | $61.91K | 18,371 |
| David R. Maraldo EVP & Pres. MMD | May 2, 2026 | Tax withholding | −159 | $112.16 | $17.83K | 18,212 |
| Betty D. Larson EVP, Chief HR Officer | Apr 30, 2026 | Tax withholding | −5,143 | $110.95 | $570.62K | 13,774 |
| Betty D. Larson EVP, Chief HR Officer | Apr 30, 2026 | Option exercise | +11,350 | $110.95 | $1.26M | 18,917 |
| Dalton E. Smart III SVP Fin. - Global Controller | Apr 30, 2026 | Option exercise | +464 | $110.95 | $51.48K | 9,296 |
| Dalton E. Smart III SVP Fin. - Global Controller | Apr 30, 2026 | Tax withholding | −159 | $110.95 | $17.64K | 9,137 |
| Johannes Jacobus Oosthuizen EVP, Oncology & Int?l | Apr 29, 2026 | Option exercise | +1,377 | $110.03 | $151.51K | 22,574 |
| Johannes Jacobus Oosthuizen EVP, Oncology & Int?l | Apr 29, 2026 | Tax withholding | −679 | $110.03 | $74.71K | 21,895 |
| Caroline Litchfield EVP & CFO | Apr 29, 2026 | Option exercise | +3,935 | $110.03 | $432.97K | 94,239 |
| Caroline Litchfield EVP & CFO | Apr 29, 2026 | Tax withholding | −1,938 | $110.03 | $213.24K | 92,301 |
| Betty D. Larson EVP, Chief HR Officer | Apr 29, 2026 | Option exercise | +2,085 | $110.03 | $229.41K | 8,282 |
| Betty D. Larson EVP, Chief HR Officer | Apr 29, 2026 | Tax withholding | −715 | $110.03 | $78.67K | 7,567 |
| Jennifer Zachary EVP, General Counsel | Apr 29, 2026 | Option exercise | +2,951 | $110.03 | $324.70K | 72,351 |
| Jennifer Zachary EVP, General Counsel | Apr 29, 2026 | Tax withholding | −1,454 | $110.03 | $159.98K | 70,897 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Apr 29, 2026 | Tax withholding | −1,241 | $110.03 | $136.55K | 161,537 |
| Richard R. DeLuca EVP&Pres, Merck Animal Heallth | Apr 29, 2026 | Option exercise | +2,518 | $110.03 | $277.06K | 162,778 |
| Chirfi Guindo EVP, Access, Policy & Comms | Apr 29, 2026 | Option exercise | +1,967 | $110.03 | $216.43K | 62,582 |
| Chirfi Guindo EVP, Access, Policy & Comms | Apr 29, 2026 | Tax withholding | −969 | $110.03 | $106.62K | 61,613 |
| David Michael Williams EVP,Chief Info&Digital Officer | Apr 29, 2026 | Option exercise | +1,377 | $110.03 | $151.51K | 32,395 |
| David Michael Williams EVP,Chief Info&Digital Officer | Apr 29, 2026 | Tax withholding | −679 | $110.03 | $74.71K | 31,716 |
| Sanat Chattopadhyay Exe V-P & Pres. MMD | Apr 29, 2026 | Tax withholding | −1,130 | $110.03 | $124.33K | 15,347 |
| Sanat Chattopadhyay Exe V-P & Pres. MMD | Apr 29, 2026 | Option exercise | +2,597 | $110.03 | $285.75K | 16,477 |
| Dalton E. Smart III SVP Fin. - Global Controller | Apr 29, 2026 | Option exercise | +944 | $110.03 | $103.87K | 9,156 |
| Dalton E. Smart III SVP Fin. - Global Controller | Apr 29, 2026 | Tax withholding | −324 | $110.03 | $35.65K | 8,832 |
| Robert M. Davis Chairman, CEO & President, Director | Apr 29, 2026 | Option exercise | +13,300 | $110.03 | $1.46M | 456,902 |
| Robert M. Davis Chairman, CEO & President, Director | Apr 29, 2026 | Tax withholding | −6,551 | $110.03 | $720.81K | 450,351 |
| Dean Y. Li Executive VP & President, MRL | Apr 29, 2026 | Tax withholding | −2,326 | $110.03 | $255.93K | 94,431 |
| Dean Y. Li Executive VP & President, MRL | Apr 29, 2026 | Option exercise | +4,722 | $110.03 | $519.56K | 96,757 |
| Chirfi Guindo Chief Marketing Officer | Feb 12, 2026 | Sale | −10,000 | $121.46 | $1.21M | 60,615 |
| Dean Y. Li Executive VP & President, MRL | Feb 10, 2026 | Sale | −10,235 | $117.52 | $1.20M | 92,035 |
| Chirfi Guindo Chief Marketing Officer | Feb 9, 2026 | Sale | −10,000 | $118.41 | $1.18M | 70,615 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Merck's stock actually held short. Settlement fails (shares not delivered on time) peaked at 69,948 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David Michael Williams Officer | Nov 2, 2026 | 21,359 | $3.19M | Nov 2, 2026 | Exercise of Options Under a Registered Plan |
| Chirfi Guindo Officer | Aug 13, 2026 | 10,000 | $1.35M | Aug 13, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Jennifer Zachary Officer | Aug 12, 2026 | 80,315 | $10.72M | Aug 12, 2026 | Exercise of Options Under a Registered Plan |
| Richard Robert Deluca Jr Officer | Aug 12, 2026 | 11,699 | $1.54M | Aug 12, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Richard Robert Deluca Jr Officer | Aug 11, 2026 | 12,837 | $1.69M | Aug 11, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Richard Robert Deluca Jr Officer | Aug 10, 2026 | 20,784 | $2.71M | Aug 10, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Chirfi Guindo Officer | Aug 6, 2026 | 15,000 | $1.97M | Aug 6, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Richard Robert Deluca Jr Officer | Aug 6, 2026 | 6,050 | $788.77K | Aug 6, 2026 | Restricted Stock Vesting Under a Registered Plan |
| David Michael Williams Officer | Aug 5, 2026 | 52,847 | $6.81M | Aug 5, 2026 | Exercise of Options Under a Registered Plan |
| David R. Maraldo Officer | Aug 5, 2026 | 18,706 | $2.41M | Aug 5, 2026 | Exercise of Options Under a Registered Plan |
| Chirfi Guindo Officer | Feb 13, 2026 | 20,000 | $2.37M | Feb 9, 2026 | Restricted stock vesting under a registered plan |
| Dean Y. Li Officer | Feb 10, 2026 | 10,235 | $1.20M | Feb 10, 2026 | Restricted stock vesting under a registered plan |
| Jennifer Zachary Officer | Feb 9, 2026 | 121,573 | $14.49M | Feb 9, 2026 | Exercise of options under a registered plan |
| Chirfi Guindo Officer | Feb 9, 2026 | 20,000 | $2.37M | Feb 9, 2026 | Restricted stock vesting under a registered plan |
| Richard Robert Deluca Jr. Officer | Feb 6, 2026 | 37,685 | $4.56M | Feb 6, 2026 | Restricted stock vesting under a registered plan |
Congress trades
40 trades in Merck reported by 17 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Maria Elvira Salazar FL27 | Sold (part) | Sep 24, 2026 | $1K–15K | Oct 7, 2026 |
| Michael T. McCaul TX10 · spouse | Sold | Aug 28, 2026 | $50K–100K | Oct 14, 2026 47 days late |
| Maria Elvira Salazar FL27 | Bought | Aug 19, 2026 | $15K–50K | Sep 9, 2026 |
| Maria Elvira Salazar FL27 | Bought | Aug 19, 2026 | $15K–50K | Sep 9, 2026 |
| Josh Gottheimer NJ05 · joint account | Bought | Feb 4, 2026 | $1K–15K | Mar 16, 2026 |
| Michael T. McCaul TX10 · spouse | Sold | Jan 13, 2026 | $15K–50K | Feb 11, 2026 |
| Gilbert Cisneros CA31 | Bought | Dec 19, 2025 | $1K–15K | Jan 12, 2026 |
| Julie Johnson TX32 · joint account | Sold | Dec 18, 2025 | $1K–15K | Jan 15, 2026 |
| Gilbert Cisneros CA31 | Bought | Nov 18, 2025 | $1K–15K | Dec 15, 2025 |
| Julie Johnson TX32 · joint account | Sold (part) | Nov 13, 2025 | $1K–15K | Dec 11, 2025 |
| Valerie Hoyle OR04 · spouse | Sold | Sep 23, 2025 | $1K–15K | Oct 10, 2025 |
| Marjorie Taylor Greene GA14 | Bought | Aug 28, 2025 | $1K–15K | Aug 29, 2025 |
| Julie Johnson TX32 · joint account | Sold (part) | Aug 14, 2025 | $1K–15K | Sep 11, 2025 |
| Gilbert Cisneros CA31 | Bought | Aug 5, 2025 | $1K–15K | Sep 12, 2025 |
| Lisa McClain MI09 · spouse | Sold | Aug 4, 2025 | $1K–15K | Sep 12, 2025 |
| Ritchie John Torres NY15 | Sold | Jul 11, 2025 | $1K–15K | Aug 20, 2025 |
| Lisa McClain MI09 · spouse | Bought | Jun 24, 2025 | $1K–15K | Aug 13, 2025 50 days late |
| Scott Scott Franklin FL18 · joint account | Sold | Jun 16, 2025 | $1K–15K | Jul 14, 2025 |
| Julie Johnson TX32 · joint account | Bought | Jun 13, 2025 | $1K–15K | Jul 14, 2025 |
| Gilbert Cisneros CA31 | Sold | May 30, 2025 | $1K–15K | Jun 6, 2025 |
| Rob Bresnahan PA08 | Sold | May 15, 2025 | $15K–50K | May 31, 2025 |
| Marjorie Taylor Greene GA14 | Bought | May 5, 2025 | $1K–15K | May 6, 2025 |
| Gilbert Cisneros CA31 | Bought | Apr 29, 2025 | $1K–15K | May 6, 2025 |
| Bruce Westerman AR04 | Sold | Apr 21, 2025 | $1K–15K | May 12, 2025 |
| Jefferson Shreve IN06 | Sold | Apr 17, 2025 | $15K–50K | May 8, 2025 |
| Marjorie Taylor Greene GA14 | Bought | Apr 9, 2025 | $1K–15K | Apr 11, 2025 |
| Rob Bresnahan PA08 | Bought | Apr 8, 2025 | $15K–50K | May 8, 2025 |
| Gilbert Cisneros CA31 | Sold (part) | Mar 31, 2025 | $15K–50K | Apr 7, 2025 |
| Kelly Louise Morrison MN03 | Sold (part) | Mar 20, 2025 | $1K–15K | Apr 11, 2025 |
| Sheri Biggs SC03 · spouse | Sold | Mar 19, 2025 | $15K–50K | Oct 5, 2025 200 days late |
| Bruce Westerman AR04 | Bought | Mar 3, 2025 | $1K–15K | Apr 16, 2025 |
| Gilbert Cisneros CA31 | Bought | Feb 26, 2025 | $15K–50K | Mar 6, 2025 |
| Rob Bresnahan PA08 | Sold | Feb 25, 2025 | $15K–50K | Mar 27, 2025 |
| Jefferson Shreve IN06 | Bought | Feb 24, 2025 | $15K–50K | Mar 9, 2025 |
| Josh Gottheimer NJ05 · joint account | Sold | Jan 27, 2025 | $15K–50K | Feb 10, 2025 |
| Gilbert Cisneros CA31 | Sold | Jan 24, 2025 | $1K–15K | Feb 11, 2025 |
| Julie Johnson TX32 · joint account | Bought | Jan 17, 2025 | $1K–15K | Feb 12, 2025 |
| Byron Donalds FL19 · spouse | Sold | Jan 16, 2025 | $1K–15K | Feb 10, 2025 |
| Byron Donalds FL19 | Sold | Jan 16, 2025 | $1K–15K | Feb 10, 2025 |
| Jared Moskowitz FL23 · child | Sold | Jan 15, 2025 | $1K–15K | Feb 10, 2025 |
See a number that looks wrong?